Skip to main content
Premium Trial:

Request an Annual Quote

Aclara Reports Flat Revenues, Widened Losses

SAN FRANCISCO, Nov. 7 - Aclara BioSciences today reported approximately flat revenue for the third quarter of 2002.

 

The company said its total revenue was $505,000 in the third quarter which ended September 30, compared to $507,000 in the same quarter of 2001.

 

Aclara reported a net loss based on generally accepted accounting principles of $11.2 million, or $.31 per share, in the third quarter 2002 compared to a net loss of $9.1 million, or $.26 per share, in the year-ago period. The company said the increased loss in part reflects higher costs associated with a focus on the commercialization of its eTag assay systems, a move the company said deemphasizes microfluidic product development and lead to the firing of approximately 50 employees.

 

R&D spending decreased to $5.4 million compared to $5.8 million in the same period a year ago.

 

Aclara also reported $85.2 million in cash, cash equivalents, and short-term investments at the end of September 2002.

 

Click here for more information.

The Scan

J&J Booster Support

A US Food and Drug Administration advisory panel has voted to support a booster dose of Johnson & Johnson's SARS-CoV-2 vaccine, according to the Los Angeles Times.

To Keep the Cases Moving

The president of the UK Royal College of Pathologists tells the Financial Times that more investment is needed to tackle a backlog of cases.

NAS Expels Archaeologist

Science reports Luis Jaime Castillo Butters' expulsion is the first of an international member from the US National Academy of Sciences.

PLOS Papers on Angelman Syndrome-Like Cases, Salmonella Paratyphi A, SARS-CoV-2 in Brazil

In PLOS this week: exome sequencing analysis of Angelman syndrome-like cases, genetic epidemiology of Salmonella Paratyphi A, and more.